230 related articles for article (PubMed ID: 32199866)
1. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials.
Heier JS; Pieramici D; Chakravarthy U; Patel SS; Gupta S; Lotery A; Lad EM; Silverman D; Henry EC; Anderesi M; Tschosik EA; Gray S; Ferrara D; Guymer R;
Ophthalmol Retina; 2020 Jul; 4(7):673-688. PubMed ID: 32199866
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
[TBL] [Abstract][Full Text] [Related]
3. Macular Sensitivity Endpoints in Geographic Atrophy: Exploratory Analysis of Chroma and Spectri Clinical Trials.
Chang DS; Callaway NF; Steffen V; Csaky K; Guymer RH; Birch DG; Patel PJ; Ip M; Gao SS; Briggs J; Honigberg L; Lai P; Ferrara D; Sepah YJ
Ophthalmol Sci; 2024; 4(1):100351. PubMed ID: 37869030
[TBL] [Abstract][Full Text] [Related]
4. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
[TBL] [Abstract][Full Text] [Related]
5. Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.
Fu DJ; Bagga P; Naik G; Glinton S; Faes L; Liefers B; Lima R; Wignall G; Keane PA; Ioannidou E; Ribeiro Reis AP; McKeown A; Scheibler L; Patel PJ; Moghul I; Pontikos N; Balaskas K
JAMA Ophthalmol; 2024 Jun; 142(6):548-558. PubMed ID: 38722644
[TBL] [Abstract][Full Text] [Related]
6. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
Holekamp N; Wykoff CC; Schmitz-Valckenberg S; Monés J; Souied EH; Lin H; Rabena MD; Cantrell RA; Henry EC; Tang F; Swaminathan B; Martin J; Ferrara D; Staurenghi G
Ophthalmology; 2020 Jun; 127(6):769-783. PubMed ID: 32081489
[TBL] [Abstract][Full Text] [Related]
7. Complement inhibitors for age-related macular degeneration.
Tzoumas N; Riding G; Williams MA; Steel DH
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
[TBL] [Abstract][Full Text] [Related]
8. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
Rosenfeld PJ; Dugel PU; Holz FG; Heier JS; Pearlman JA; Novack RL; Csaky KG; Koester JM; Gregory JK; Kubota R
Ophthalmology; 2018 Oct; 125(10):1556-1567. PubMed ID: 29716784
[TBL] [Abstract][Full Text] [Related]
9. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
10. Maximum Reading Speed in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Varma R; Souied EH; Tufail A; Tschosik E; Ferrara D; Zhang J; Silverman D; Dolan C; Bressler NM
Invest Ophthalmol Vis Sci; 2018 Mar; 59(4):AMD195-AMD201. PubMed ID: 30383205
[TBL] [Abstract][Full Text] [Related]
11. Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial.
Kim BJ; Hunter A; Brucker AJ; Hahn P; Gehrs K; Patel A; Edwards AO; Li Y; Khurana RN; Nissim I; Daniel E; Grunwald J; Ying GS; Pistilli M; Maguire MG; Dunaief JL
Ophthalmol Retina; 2020 Sep; 4(9):889-898. PubMed ID: 32418846
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy: Analysis of the Phase III Chroma and Spectri Trials.
Edmonds R; Steffen V; Honigberg LA; Chang MC
Ophthalmol Sci; 2023 Dec; 3(4):100301. PubMed ID: 37304044
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of incident geographic atrophy in the complications of age-related macular degeneration prevention trial.
Brader HS; Ying GS; Martin ER; Maguire MG;
Ophthalmology; 2013 Sep; 120(9):1871-9. PubMed ID: 23622873
[TBL] [Abstract][Full Text] [Related]
14. Alternative Complement Pathway Inhibition by Lampalizumab: Analysis of Data From Chroma and Spectri Phase III Clinical Trials.
Edmonds R; Steffen V; Honigberg LA; Chang MC
Ophthalmol Sci; 2023 Sep; 3(3):100286. PubMed ID: 37228694
[TBL] [Abstract][Full Text] [Related]
15. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration.
Sunness JS; Rubin GS; Broman A; Applegate CA; Bressler NM; Hawkins BS
Ophthalmology; 2008 Sep; 115(9):1480-8, 1488.e1-2. PubMed ID: 18486216
[TBL] [Abstract][Full Text] [Related]
16. The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Fleckenstein M; Mitchell P; Freund KB; Sadda S; Holz FG; Brittain C; Henry EC; Ferrara D
Ophthalmology; 2018 Mar; 125(3):369-390. PubMed ID: 29110945
[TBL] [Abstract][Full Text] [Related]
17. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kuppermann BD; Patel SS; Boyer DS; Augustin AJ; Freeman WR; Kerr KJ; Guo Q; Schneider S; López FJ;
Retina; 2021 Jan; 41(1):144-155. PubMed ID: 32134802
[TBL] [Abstract][Full Text] [Related]
18. Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan.
Steinle NC; Pearce I; Monés J; Metlapally R; Saroj N; Hamdani M; Ribeiro R; Rosenfeld PJ; Lad EM
Am J Ophthalmol; 2021 Jul; 227():116-124. PubMed ID: 33675755
[TBL] [Abstract][Full Text] [Related]
19. Relationship of Topographic Distribution of Geographic Atrophy to Visual Acuity in Nonexudative Age-Related Macular Degeneration.
Shen LL; Sun M; Ahluwalia A; Young BK; Park MM; Toth CA; Lad EM; Del Priore LV
Ophthalmol Retina; 2021 Aug; 5(8):761-774. PubMed ID: 33212271
[TBL] [Abstract][Full Text] [Related]
20. Functional Reading Independence (FRI) Index: A New Patient-Reported Outcome Measure for Patients With Geographic Atrophy.
Kimel M; Leidy NK; Tschosik E; Dolan C; Souied EH; Varma R; Bressler NM
Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):6298-6304. PubMed ID: 27893095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
